Debt + Reliance on Price Increases vs. R&D?
I don't follow CXR closely, but it is my understanding that in addition to their rather sizeable debt, CXR relies heavily on drug price increases to drive revenue vs. research, development, and production of their own products.....If so, I think there may be a lot of pain to come as Valeant is called onto the carpet by the U.S. Congress and drug price increases will likely be scrutinized more closely, not to mention Hillary Clinton's comments on drug price gouging and her desire to put a stop to it......I think she's the odds-on-favorite to become the next President, and I think Congress will be pressured by citizens both Democratic and Republican to reign in drug costs......